The Texas-Taiwan Biotechnology Seminar strengthens the connection between U.S. biotechnology and Taiwan. Expanded coverage of liver cancer targeted drugs is expected to benefit 800 patients. Find a way out through genes. Clinical application of gene technology. International Genomics Conference unveils China The mystery of the gene bank
"Taiwan Healthcare + International Portal Platform" was officially launched on December 23, bringing together hundreds of top companies and institutions in the three major fields of biopharmaceuticals, innovative medical materials and medical care. Vice President Chen Jianren, founder of the Biotechnology Council Wang Jinping, Minister of Health and Welfare Lin Zuoyen, representatives of THP medical institutes and biotechnology industries in various fields, as well as business leaders from various countries stationed in Taiwan jointly launched the online launch, officially serving the international community, and held The 19th National Biotechnology and Medical Quality Award Ceremony presented the 30 award-winning medical teams and biomedical products in 2016. The Innovation? Quality? Taiwan Healthcare+ Biomedical Innovation Technology Joint Exhibition was also held on site, and nearly 50 new innovative technology products were held. Exhibited on site. Guoding Biotech's Hocena new cancer and chronic disease drug won the National Innovation Award
Guoding Biotech won the 13th National Innovation Award for its "Hocena - a new cancer drug and clinical progress of a new drug for chronic diseases" Enterprise Innovation Award", this new small molecule drug is currently undergoing phase II human clinical trials for non-small cell lung cancer under the supervision of the FDA in the United States and Taiwan. In addition to actively accepting human clinical trials for lung cancer, it has also recently launched a global The large-scale Phase II human clinical trial of pancreatic cancer actively intervenes in the treatment of first-line pancreatic cancer patients through a combined treatment model. After confirming the efficacy of human body, it captures the global market of pancreatic cancer drugs. In addition, Antroquinonol also In 2015, it obtained orphan drug certification from the US FDA for the treatment of pancreatic cancer, acute myeloid leukemia (blood cancer) and liver cancer. The pancreatic cancer clinical trial currently being carried out has the opportunity to confirm the efficacy of the treatment after completing the second phase clinical trial. Once approved, you can apply for marketing authorization (NDA). Taihe Biotechnology Pediatric ADHD Patch
Taihe R&D team selected commonly used drugs, low bioavailability, and short-acting main ingredients, and used its own Trasnsdermal DDS technology to conduct research and development, focusing on the development of patches. The product focuses on diseases of the elderly and children, such as ADHD and Alzheimer's disease. The new dosage form of the patch product has long-term effect and long-term consistent blood concentration, which increases the patient's convenience of use and medical advice. New ITRI Chuang Biotechnology Company's "Jusheng Biomedical" develops niche nano-drugs
Jusheng Biomedical's IOP Injection nano-iron oxide drug was selected as an index case by the Center for Drug Examination (CDE) this year, 2 In the same month, it was evaluated by the Industrial Bureau of the Ministry of Economic Affairs as complying with the "Regulations on the Development of the New Biotechnology Drug Industry". In the same month, it started cooperating with Taipei Rongzhong to conduct the first phase clinical trial of IOP Injection. The market demand for iron supplementation in patients with kidney disease is very huge. Every year, intravenous injections are administered all over the world. The iron supplement market has reached more than 1.6 billion US dollars. IOP Injection, a nano-iron oxide drug, can supplement iron supplements through a single injection without the need for fractional treatments to meet the rapidly increasing demand for iron supplements. The use of polyethanol as an excipient causes less allergic side effects than similar products, can avoid severe allergic reactions and is safer. Clinical data of enterovirus 71 vaccine for infants aged 2-6 months with KIA vaccine
Among all types, enterovirus 71 poses the greatest threat to young children. Due to the immune system of infants under 6 months of age Not yet mature, Kya Vaccine targets infants and young children between 2 and 6 months old to develop enterovirus 71 vaccine. It is the only development in the world that has clinical data for infants and young children between 2 and 6 months old.
Quansheng Biotech’s new anti-allergic antibody drug
The new anti-allergic antibody drug FB825 (Anti-CεmX), which is a collaboration with Academia Sinica, has obtained a complete U.S. drug and efficacy patent (8,460,664). Anti-CεmX is a huge new drug market for the treatment of allergic diseases in the world, and has completed in vitro, in vivo, human specimen and safety-related trials.
Anti-CεmX antibody can directly kill B cells expressing IgE and block the production of IgE. It has the potential to prevent and treat allergic diseases. It is also the only new anti-allergic antibody drug in the world that can compete with Xolair. Sinochem Health has developed a small molecule functional peptide "Keffel peptide"
Sinochem Health won the title of "Application and Development of Novel Kefir Peptide in the Health Industry" at the 13th National Innovation "Award-winning" for sure.
"Kefir peptide" was completely developed by a Taiwanese team, with the parent company Sinochem Pharmaceuticals and the research team of President Chen Quanmu of the National Chung Hsing University Academy of Sciences. After ten years of industry-university alliance, through industry, government, and academia, Integrating cross-border resources between medicine and medicine, using natural "Kefir grains" as the key technology for the development of fermentation bacteria, we successfully mass-produced the small molecule functional peptide "Kefir peptide". The production process does not require any chemical addition and extraction procedures, and is in line with the requirements of small molecule functional peptides. The international trend of molecular, natural and additive-free products with scientifically proven efficacy. "Kefir peptide" mainly has four major innovation advantages, including: core biological fermentation technology, scientific evidence of health care efficacy, complete international patent layout, and diversified product extensions. Currently, it has obtained patents from the United States, Taiwan, China, and the European Union (UK). , France, Germany, the Netherlands, Switzerland, Luxembourg, Ireland) and other countries), and settled in the Central Science Park in July this year to establish the "Kefir Peptide" R&D Center, based on scientific verification, to enable the core technology products to be marketed at home and abroad.
The overall R&D of Taiwan’s biotechnology industry has been moving towards projects that are more internationally competitive. Each team has a longer-term and complete R&D plan, which represents the follow-up marketing process, regulations, international patents, and multinational clinical trials. As it becomes more mature, the overall success rate and opportunities for new ventures to enter the market in the future will be greatly improved. Topic: Student Policy Conference